248 related articles for article (PubMed ID: 14654778)
21. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response.
Golding SE; Rosenberg E; Neill S; Dent P; Povirk LF; Valerie K
Cancer Res; 2007 Feb; 67(3):1046-53. PubMed ID: 17283137
[TBL] [Abstract][Full Text] [Related]
22. cAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner.
Hecquet C; Lefevre G; Valtink M; Engelmann K; Mascarelli F
Oncogene; 2002 Sep; 21(39):6101-12. PubMed ID: 12203122
[TBL] [Abstract][Full Text] [Related]
23. Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells.
Sippel RS; Carpenter JE; Kunnimalaiyaan M; Lagerholm S; Chen H
Am J Physiol Gastrointest Liver Physiol; 2003 Aug; 285(2):G245-54. PubMed ID: 12851216
[TBL] [Abstract][Full Text] [Related]
24. MAP kinase-dependent degradation of p27Kip1 by calpains in choroidal melanoma cells. Requirement of p27Kip1 nuclear export.
Delmas C; Aragou N; Poussard S; Cottin P; Darbon JM; Manenti S
J Biol Chem; 2003 Apr; 278(14):12443-51. PubMed ID: 12529328
[TBL] [Abstract][Full Text] [Related]
25. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
[TBL] [Abstract][Full Text] [Related]
26. Regulation of p53 expression by the RAS-MAP kinase pathway.
Agarwal ML; Ramana CV; Hamilton M; Taylor WR; DePrimo SE; Bean LJ; Agarwal A; Agarwal MK; Wolfman A; Stark GR
Oncogene; 2001 May; 20(20):2527-36. PubMed ID: 11420662
[TBL] [Abstract][Full Text] [Related]
27. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
Romerio F; Riva A; Zella D
Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
[TBL] [Abstract][Full Text] [Related]
28. MEK kinase activity is not necessary for Raf-1 function.
Hüser M; Luckett J; Chiloeches A; Mercer K; Iwobi M; Giblett S; Sun XM; Brown J; Marais R; Pritchard C
EMBO J; 2001 Apr; 20(8):1940-51. PubMed ID: 11296227
[TBL] [Abstract][Full Text] [Related]
29. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein.
Giambartolomei S; Covone F; Levrero M; Balsano C
Oncogene; 2001 May; 20(20):2606-10. PubMed ID: 11420671
[TBL] [Abstract][Full Text] [Related]
30. Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells.
Ravi RK; Thiagalingam A; Weber E; McMahon M; Nelkin BD; Mabry M
Am J Respir Cell Mol Biol; 1999 Apr; 20(4):543-9. PubMed ID: 10100985
[TBL] [Abstract][Full Text] [Related]
31. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation.
Lahlou H; Saint-Laurent N; Estève JP; Eychène A; Pradayrol L; Pyronnet S; Susini C
J Biol Chem; 2003 Oct; 278(41):39356-71. PubMed ID: 12878607
[TBL] [Abstract][Full Text] [Related]
32. Dual functions for OVAAL in initiation of RAF/MEK/ERK prosurvival signals and evasion of p27-mediated cellular senescence.
Sang B; Zhang YY; Guo ST; Kong LF; Cheng Q; Liu GZ; Thorne RF; Zhang XD; Jin L; Wu M
Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11661-E11670. PubMed ID: 30478051
[TBL] [Abstract][Full Text] [Related]
33. Sustained activation of the raf-MEK-ERK pathway elicits cytokine unresponsiveness in T cells.
Chen D; Heath V; O'Garra A; Johnston J; McMahon M
J Immunol; 1999 Dec; 163(11):5796-805. PubMed ID: 10570262
[TBL] [Abstract][Full Text] [Related]
34. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway.
Coles LC; Shaw PE
Oncogene; 2002 Mar; 21(14):2236-44. PubMed ID: 11948406
[TBL] [Abstract][Full Text] [Related]
35. B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.
Cui Y; Guadagno TM
Oncogene; 2008 May; 27(22):3122-33. PubMed ID: 18071315
[TBL] [Abstract][Full Text] [Related]
36. Status of RASSF1A in uveal melanocytes and melanoma cells.
Calipel A; Abonnet V; Nicole O; Mascarelli F; Coupland SE; Damato B; Mouriaux F
Mol Cancer Res; 2011 Sep; 9(9):1187-98. PubMed ID: 21788308
[TBL] [Abstract][Full Text] [Related]
37. The tumour suppressor DiRas3 interacts with C-RAF and downregulates MEK activity to restrict cell migration.
Klingauf M; Beck M; Berge U; Turgay Y; Heinzer S; Horvath P; Kroschewski R
Biol Cell; 2013 Feb; 105(2):91-107. PubMed ID: 23157514
[TBL] [Abstract][Full Text] [Related]
38. Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src.
Aziz N; Cherwinski H; McMahon M
Mol Cell Biol; 1999 Feb; 19(2):1101-15. PubMed ID: 9891045
[TBL] [Abstract][Full Text] [Related]
39. Tuberous sclerosis-2 tumor suppressor modulates ERK and B-Raf activity in transformed renal epithelial cells.
Yoon HS; Ramachandiran S; Chacko MA; Monks TJ; Lau SS
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F417-24. PubMed ID: 14612383
[TBL] [Abstract][Full Text] [Related]
40. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf.
Brummer T; Naegele H; Reth M; Misawa Y
Oncogene; 2003 Dec; 22(55):8823-34. PubMed ID: 14654779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
